A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Stopped early · Phase 2

Conditions studied: Cancer, Prostate

In brief

The purpose of this study is to assess the safety and efficacy of siltuximab administered in combination with mitoxantrone and prednisone in participants with metastatic (spread of cancer cells from one part of the body to another) hormone-refractory (not responding to treatment) prostate cancer (abnormal tissue that grows and spreads in the body) (HRPC).

Key facts

Study ID

NCT00385827

Run by

Centocor, Inc.

People needed

106

Starts

2006-11-01

Expected to finish

2008-11-01

Last updated by the study team

2014-08-20

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histologically (the study of tissue under the microscope) or cytologically (the study of cells) confirmed adenocarcinoma (a malignant epithelial tumor with a glandular organization) of the prostate
• Radiologically (Gamma and Computed Topography [CT] scans) documented metastatic disease
• At least 6 weeks of treatment with 1 prior docetaxel-based chemotherapy for metastatic Hormone Refractory Prostate Cancer (HRPC)
• Disease progression, during or within 6 months of stopping of prior docetaxel-based therapy, based on one of the following: serum Prostate Specific Antigen (PSA) progression, defined as a rise in at least 2 consecutive serum PSA values, each obtained at least 1 week apart or radiologic disease progression: if disease progression is shown by bone scan only, then disease progression is defined by the appearance of 2 or more new bone lesions (abnormal area of tissue, such as a wound, sore, rash, or boil)
• Orchiectomy (surgery to remove one or both testicles) or testosterone less than 50 nanogram per decilliter (ng/dL) by means of pharmacological/chemical castration

You may not qualify if…

• No evidence of a brain tumor
• No more than 1 line of chemotherapy for metastatic prostate cancer
• No prior mitoxantrone treatment
• Prior malignancy (other than prostate cancer) except adequately treated superficial bladder cancer, basal cell or squamous cell carcinoma (type of cancer) of the skin, or other cancer for which the subject has been disease-free for atleast 3 years
• No Human Immunodeficiency Virus (HIV) (a life-threatening infection that you can get from an infected person's blood or from having sex with an infected person) seropositivity or hepatitis (inflammation of the liver) B or C infection

Where it is running

• Study site — Norwalk, Connecticut, United States
• Study site — Port Saint Lucie, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Shreveport, Louisiana, United States
• Study site — Baltimore, Maryland, United States
• Study site — St Louis, Missouri, United States
• Study site — New York, New York, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Charleston, South Carolina, United States
• Study site — North Charleston, South Carolina, United States
• Study site — Milwaukee, Wisconsin, United States
• Study site — Innsbruck, Austria
• Study site — Sankt Veit an der Glan, Austria
• Study site — Vienna, Austria
• Study site — Wels, Austria
• Study site — Aalst, Belgium
• Study site — Antwerp, Belgium
• Study site — Brasschaat, Belgium
• Study site — Brussels, Belgium
• Study site — Roeselare, Belgium
• Study site — Sint-Niklaas, Belgium
• Study site — Wilrijk, Belgium
• Study site — Caen, France
• Study site — Le Mans, France
• Study site — Lyon, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.